1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 2: Clinical scales of baseline and month 12 (median and range)^{^a}
Time Point Baseline Month 12 P Value
Patients on natalizumab 
    EDSS 3.0 (1.5–6.5) 3.0 (1.0–6.5) 1.0
    HADS-A 6.0 (1–13) 6.0 (0–15) 1.0
    HADS-D 4.5 (0–18) 2.0 (0–17) .012^{^b}
    CIS-20 68.5 (14–125) 62.0 (10–117) .036
Patients on IFNb/GA (n = 17) 
    EDSS 2.5 (1.0–6.5) 3.0 (1.5–7.0) .006^{^b}
    HADS-A 7.0 (1–14) 5.0 (1–11) .609
    HADS-D 5.0 (0–12) 3.0 (0–14) .855
    CIS-20 86.0 (31–114) 81.0 (16–105) .177
Healthy controls (n = 12) 
    HADS-A 3.5 (1–12) 2.5 (0–9) 1.0
    HADS-D 1.0 (0–10) 0.0 (0–5) 1.0
    CIS-20 42.5 (17–85) 52.0 (17–82) .744
Note:—CIS-20 indicates Checklist Individual Strength questionnaire; HADS, Hospital Anxiety and Depression Scale; A, Anxiety; D, Depression.
↵a EDSS, HADS, and CIS were tested with the related-samples Wilcoxon signed rank test (Bonferroni-corrected).
↵b Significant difference.